SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Actinium Pharmaceuticals Inc Is Being Looked Into By The Schall Law Firm For Possible Securities Law Violations And Stockholders Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses In Actinium Pharmaceuticals Inc Are Encouraged To Join An Investigation Into Securities Fraud With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholders In Actinium Pharmaceuticals Inc Urged To Participate In A Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about Securities Fraud Investigation - ATNM
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Stockholders With Losses In Actinium Pharmaceuticals Inc Urged To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ATNM
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
